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Purpose: To investigate factors influencing the evaluation of background 
parenchymal enhancement (BPE) at follow-up breast magnetic resonance imaging 
(MRI) after adjuvant endocrine therapy.
Materials and Methods: One hundred twelve women with breast cancer and MRI 
of the contralateral unaffected breast before and after endocrine therapy were 
identified. Two readers in consensus performed blinded side-by-side comparison of 
BPE (minimal, mild, moderate, and marked) before and after therapy with categorical 
scales. Age, body mass index, menopausal status, treatment regimen (selective 
estrogen receptor modulator or aromatase inhibitor), chemotherapy, follow-up 
duration, BPE at baseline MRI, MRI field strength before and after therapy, and 
recurrence were analyzed for their influences on decreased BPE. 
Results: Younger age, premenopausal status, treatment with selective estrogen 
receptor modulator, MRI field strength, and moderate or marked baseline BPE were 
significantly associated with decreased BPE. In multivariate analysis, MRI field 
strength and baseline BPE showed a significant association.
Conclusion: MRI field strength and baseline BPE before and after therapy .were 
associated with decreased BPE at post-therapy, follow-up MRI.
Keywords: Breast cancer; Antineoplastic agents; Hormonal; Magnetic resonance 
imaging
INTRODUCTION
Considering that at least 70% of breast cancers are classified as estrogen receptor-
positive breast cancers, adjuvant endocrine therapy designed to interfere with estrogen 
action has been a mainstay of breast cancer treatment. Tamoxifen is a selective 
estrogen receptor modulator (SERM) that was the first and so far most successful 
targeted cancer therapy. Novel and effective endocrine therapies have been developed 
that target estrogen synthesis, such as aromatase inhibitors (AIs) (1). Still, late 
recurrences remain common in estrogen receptor-positive breast cancer survivors, with 
rates of 2.5% per year for 20 years with Tamoxifen treatment and about 2% per year 
with AI for the 10 years (2, 3). Effective biomarkers of hormonal treatment response 
are needed, but little information is available of a host factor indicating individual 
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susceptibility to endocrine agents (3, 4).
Breast magnetic resonance imaging (MRI) is often used 
following breast cancer surgery to monitor for recurrent 
disease (5). Breast vascularity and composition are 
influenced by hormonal changes, which are often visible in 
MRI as differences in background parenchymal enhancement 
(BPE) and amount of fibroglandular tissue (6, 7). BPE is an 
imaging characteristic of normal breast parenchyma defined 
by the volume and intensity of normal fibroglandular 
breast tissue enhancement after administration of an 
intravenous contrast agent. Although the underlying biologic 
mechanism of changes and variability in BPE within and 
between individuals is not well understood, previous studies 
have demonstrated the effects of physiologic hormonal 
status (8-10), hormone therapy (11, 12), and anti-estrogen 
medications (13-16) on BPE. In particular, as a potential 
marker of response in the adjuvant setting, a significant 
association was reported between endocrine agents and 
visible decreases in BPE (6, 7, 14, 15). The possible effects 
of potential confounders such as reproductive history, body 
habitus, concomitant medications, or MRI-related factors 
have been little considered.
This study was performed to investigate factors 
influencing the BPE at follow-up breast MRI after adjuvant 
endocrine therapy.
MATERIALS AND METHODS
The present retrospective study was conducted with 
Institutional Review Board approval and a waiver of patient 
informed consent.
Patients
Between January 2007 and March 2012, 1245 breast 
cancer surgeries were performed at our institution. After 
review of medical records, 674 women who underwent 
adjuvant endocrine therapy after breast cancer surgery 
were identified. Of these, 164 women with breast cancer 
underwent breast MRI before and after adjuvant endocrine 
therapy. Among them, 122 women with breast cancer and 
MRI of contralateral unaffected breast before and after 
adjuvant endocrine therapy were included in the present 
study. The mean time interval from baseline MRI to the 
beginning of adjuvant endocrine therapy, and from the 
beginning of adjuvant endocrine therapy to follow-up MRI 
was 3.0 ± 2.7 months and 28.3 ± 17.0 months, respectively. 
The remaining 42 women were excluded because of 
bilateral breast cancer (n = 19), distant metastasis observed 
before the start of endocrine therapy (n = 2), absence of 
MRI of the contralateral untreated breast (n = 15), or loss 
to follow-up (n = 6). 
MRI Technique
Breast MRI was performed using a 1.5T (Magnetom 
Avanto; Siemens, Erlangen, Germany) or a 3.0T system 
(Intera Achieva; Philips Medical Systems, Best, the 
Netherlands, Discovery MR 750; GE Healthcare, Waukesha, 
WI, USA) with a dedicated surface breast coil. Pulse 
sequence parameters for pre- and post-contrast T1-
weighted images are given in Table 1. Dynamic contrast-
enhanced MRI examination was performed with axial 
imaging, with one pre-contrast and five post-contrast 
dynamic series performed 90, 150, 210, 270, and 330 s after 
bolus injection of 0.1 mmol gadopentetate dimeglumine 
(Magnevist; Bayer Healthcare Pharmaceuticals, Montville, 
NJ, USA) or gadoterate meglumine (Dotarem; Guerbet, Paris, 
France) per kilogram of body weight into an antecubital 
vein. The injection rate was 2 mL/s, followed by an 18-mL 
saline flush. After the examination, subtraction images were 
obtained by subtracting the unenhanced images from all 
contrast-enhanced images. 
MRI Evaluation
All images were reviewed by two radiologists with 9 
and 3 years’ experience in breast MRI, respectively, who 
were blinded as to whether the MRI examinations were 
performed before or after endocrine therapy. Both readers 
in consensus performed side-by-side blinded analyses of 
the individual pairs of MRI before and after endocrine 
therapy, to increase sensitivity by comparing images at the 
same time (7). In the case of 22 women who underwent 
follow-up MRI more than once, only their first follow-up 
MRI examinations were analyzed. In the unaffected breast, 
BPE of the entire normal breast parenchyma was visually 
assessed on the basis of criteria as minimal, mild, moderate, 
or marked using a combination of pre- and post-contrast 
T1-weighted and subtraction images obtained 90, 150, 210, 
and 270 s after contrast medium injection (7, 17). 
Data and Statistical Analyses
BPE change was determined by comparing BPE before and 
after endocrine therapy. A decrease meant a downgrading 
of BPE after therapy and no decrease meant an upgrading 
of BPE or stable BPE after therapy. The percentage of 
women whose BPE decreased after endocrine therapy was 
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compared among phases of dynamic MRI 90, 150, 210, and 
270 s after contrast medium injection using the chi-square 
test. The sign test was used to determine the statistical 
significance of the difference between the number of 
women whose BPE decreased and the number of women 
whose BPE did not decrease after endocrine therapy. The 
phase of dynamic MRI showing the highest percentage of 
decrease in BPE was determined. 
Medical records were reviewed and clinical data were 
compiled as follows: patient age, body mass index (BMI), 
menopausal status, type of endocrine therapy (SERM 
[tamoxifen or toremifene] or AI [anastrozole or letrozole]), 
concomitant chemotherapy, follow-up duration from 
treatment to follow-up MRI, field strength of MRI system 
used before and after therapy (1.5T or 3.0T), and recurrence 
of breast cancer. The phase of dynamic MRI showing the 
highest percentage of decrease in BPE was used to analyze 
the association of decrease in BPE with those clinical 
variables and visually assessed BPE at baseline MRI before 
therapy using the chi-square test and two-sample t-test. 
Using variables with a statistical significance of P < 0.05 
in the univariate analysis, multivariate logistic regression 
analysis with odds ratio estimates and 95% confidence 
interval was performed to determine variables independently 
associated with decrease in BPE after endocrine therapy. 
Statistical analysis was performed with IBM SPSS Statistics, 
version 20.0.0 software (IBM Corp., Armonk, NY, USA). 
Differences were considered to be statistically significant at 
P < 0.05.
RESULTS
All phases of dynamic MRI showed significantly higher 
percentage of women whose BPE decreased than women 
whose BPE did not decrease after endocrine therapy (P 
< 0.001; Table 2). The decrease in BPE after endocrine 
therapy was significantly different according to the phase 
of dynamic MRI (P = 0.003) and the highest percentage was 
observed 150 s after contrast medium injection (79.5%, 
25/97; Table 2). Of 122 women with breast MRI obtained 
150 s after contrast medium injection, 7 (6%), 40 (33%), 
49 (40%), and 26 (21%) had minimal, mild, moderate, or 
marked BPE, respectively, before therapy, compared with 
75 (61%), 41 (34%), 6 (5%), and 0 (0%), respectively, after 
therapy. Among 25 women (25.8%) showing no decrease 
BPE after endocrine therapy, BPE increased after therapy in 
two (mild to moderate and minimal to mild, respectively).
Table 3 summarizes the results of a comparison among 
clinical and MRI variables concerning decreased BPE after 
therapy. Mean patient age was significantly different and 
women with decreased BPE were younger than those with 
no decrease in BPE (P = 0.002). Premenopausal women 
showed a significantly higher proportion of decreased BPE 
than postmenopausal women (88% vs. 59%, P = 0.001). 
Table 1. Standard MRI Protocol 
Sequences Axial T1WI Axial T1WI FS 3D-axial DCE T1WI
Magnetic field strength 1.5T 3.0T 1.5T* 3.0T 1.5T 3.0T
Echo time (ms) 11 10 - 10 1.34 1.67
Repetition time (ms) 500 526 - 643 3.7 4.5
Flip angle (degree) 90 90 - 90 12 12
Slice thickness (mm) 3 3 - 3 1.5 1.5
Field of view (cm) 33 34 - 34 33 34
Image matrix (mm × mm) 192 × 384 332 × 332 - 332 × 332 425 × 512 516 × 484
3D = three-dimensional; DCE = dynamic contrast-enhanced; FS = fat saturated; T1WI = T1-weighted image
*Axial T1WI FS was not obtained in the 1.5T MR system.
Table 2. The Percentage of Women Whose BPE Decreased after 
Adjuvant Endocrine Therapy According to the Phase of Dynamic 
MRI  
Phase* No decrease Decrease P value†
090 s 41.8 (51) 58.2 (71) < 0.001
150 s 20.5 (25) 79.5 (97) < 0.001
210 s 27.9 (34) 72.1 (88) < 0.001
270 s 28.7 (35) 71.3 (87) < 0.001
P value‡ 0.003
Numbers in parenthesis are numbers of cases.
* Phase of dynamic MR imaging obtained 90, 150, 210, and 270 s after contrast 
media injection.
† Sign test 
‡ Chi-square test
www.i-mri.org102
Background Parenchymal Enhancement in Breast MRI | Ji Hyun Youk, et al.
Women who received SERM showed a significantly higher 
proportion of decreased BPE than women who received 
AI (88% vs. 63%, P = 0.001). However, BMI, follow-up 
duration from treatment to follow-up MRI, concomitant 
chemotherapy, and recurrence of breast cancer did not show 
significant differences concerning decreased BPE. Regarding 
breast MRI, decreased BPE after treatment was significantly 
higher when the MRI field strength differed before and 
after therapy (88% vs. 67%, P = 0.005). Decreased MRI 
field strength was evident for 46 (71%) women treated 
using SERM and 19 (29%) treated using AI. No decreased 
MRI field strength was noted for 8 (89%) women treated 
with SERM and 1 (11%) treated with AI (P = 0.46). For all 
74 women in whom MRI field strength differed before and 
after therapy, pretreatment study was performed with the 
1.5T MR system followed by the 3.0-T MR system. For the 
remaining 48 women in whom field strength of MRI before 
and after therapy was the same, MRI examinations were 
performed with the 1.5T MR system in 18 women and the 
3.0-T MR system in 30 women. Moderate or marked BPE at 
baseline MRI showed significantly higher rate of a decrease 
in BPE than minimal or mild BPE at baseline (94% vs. 61%, 
P < 0.001). 
In multivariate logistic regression analysis, the difference 
Table 3. Clinical and MRI Variables According to Decrease in Background Parenchymal Enhancement after Adjuvant Endocrine 
Therapy
Variable Total
BPE after endocrine therapy
P value
No decrease Decrease
Age (years)* 48.64 ± 9.09 53.52 ± 10.05 47.39 ± 8.44 0.002
Body mass index (kg/m2)* 22.82 ± 2.81 23.22 ± 3.32 22.71 ± 2.68 0.969
Follow-up duration (months)* 28.27 ± 17.00 25.84 ± 18.83 28.90 ± 16.49 0.424
Menopause
Pre-menopause 88 (72.1%) 11 (12.5%) 77 (87.5%) 0.001
Post-menopause 34 (27.9%) 14 (41.2%) 20 (58.8%)
Treatment regimen
SERM 82 (67.2%) 10 (12.2%) 72 (87.8%) 0.001
AI 40 (32.8%) 15 (37.5%) 25 (62.5%)
Neoadjuvant chemotherapy
Yes 12 (9.8%) 1 (8.3%) 11 (91.7%) 0.272
No 110 (90.2%) 24 (21.8%) 86 (78.2%)
Adjuvant chemotherapy
Yes 56 (45.9%) 15 (26.8%) 41 (73.2%) 0.113
No 66 (54.1%) 10 (15.2%) 56 (84.8%)
Recurrence
Yes 7 (5.7%) 3 (42.9%) 4 (57.1%) 0.131
No 115 (94.3%) 22 (19.1%) 93 (80.9%)
Evaluated breast 0.165
Right 63 (51.6%) 16 (25.4%) 47 (74.6%)
Left 59 (48.4%) 9 (15.3%) 50 (84.7%)
Field strength of MRI system before and after therapy
Different 74 (60.7%) 9 (12.2%) 65 (87.8%) 0.005
Same 48 (39.3%) 16 (33.3%) 32 (66.7%)
Baseline BPE
Minimal or mild 54 (44.3%) 21 (38.9%) 33 (61.1%) < 0.001
Moderate or marked 68 (55.7%) 4 (5.9%) 64 (94.1%)
*Mean ± standard deviation.  
AI = aromatase inhibitor; BPE = background parenchymal enhancement; SERM = selective estrogen receptor modulator
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in MRI field strength before and after therapy (P = 0.004) 
and moderate or marked BPE at baseline MRI (P = 0.003) 
were significantly associated with decreased BPE after 
endocrine therapy (Table 4, Figs. 1, 2). 
DISCUSSION
Our results are consistent with previous studies showing 
that anti-estrogenic treatment is associated with decreases 
in BPE (6, 7, 14-16). Still, little has been known of the 
dynamic phase of MRI examination to assess the change in 
BPE. In general, BPE progresses over time during dynamic 
contrast-enhanced MRI (6, 18-20). In a previous study, 
the level of BPE showed a significant tendency to increase 
during dynamic contrast-enhanced MRI from the early and 
late dynamic phases (19). On the basis of these observations, 
we compared different dynamic MRI phases in terms of the 
percentage of women whose BPE decreased after endocrine 
therapy to determine the phase showing the highest 
percentage of decrease in BPE. Although the reduction of 
the average enhancements after endocrine therapy was not 
statistically significant at each phase (i.e., 1 min, 2 min, and 
6 min) in one study (6), presently the decrease in BPE after 
endocrine therapy was significantly different according 
to the phase of dynamic MRI (P = 0.003) and the highest 
percentage was observed 150 s after contrast medium 
injection (79.5%, 25/97). The possible reason to explain this 
discrepancy is uncertain but differences in populations and 
methodologic details such as the MRI acquisition protocol 
or contrast agent. Further study will be necessary using a 
second dynamic phase (150 s after contrast injection) in 
monitoring BPE after adjuvant endocrine therapy. 
Regarding the visual assessment of BPE decrease, the 
effects of potential confounders, such as reproductive 
history, body habitus, concomitant medications, or MRI-
related factors should be considered. For the treatment 
regimen, women who received SERM showed significantly 
Table 4. Results of Multivariate Logistic Regression Analysis of 
Variables Associated with Decrease in Background Parenchymal 
Enhancement after Adjuvant Endocrine Therapy
Variable Odds ratio* P value
Age 0.963 (0.887, 1.046) 0.377
Menopause
Pre-menopause 2.176 (0.534, 8.867) 0.278
Post-menopause 1
Treatment regimen
SERM 1
AI 0.950 (0.208, 4.332) 0.660 
Field strength of MR system 
   before and after therapy
Different 5.596 (1.812, 17.284) 0.003
Same 1
Baseline BPE
Minimal or mild 1 0.003
Moderate or marked 7.934 (2.029, 31.030)
*Numbers in parentheses are 95% confidence intervals.
AI = aromatase inhibitor; BPE = background parenchymal enhancement; SERM = 
selective estrogen receptor modulator 
Fig. 1. Axial contrast-enhanced 
T1-weighted subtraction MR 
images obtained 150 s after con-
trast injection in a 49-year-old 
premenopausal woman treated 
for contralateral invasive ductal 
carcinoma. (a) Baseline image 
before treatment with tamoxifen 
obtained with 1.5T MRI system 
shows moderate BPE. (b) After 
22 months from baseline study, 
follow-up 3.0T MR image during 
treatment with tamoxifen shows 
a decrease to minimal background 
parenchymal enhancement.
a b
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higher rate of a decrease in BPE than women who received 
AI (88% vs. 63%, P = 0.001), but the difference in anti-
estrogenic agent was not independently associated with 
BPE decrease in multivariate analysis. Tamoxifen is still the 
endocrine therapy of choice in premenopausal patients. AI 
is indicated only for postmenopausal and should be avoided 
in women whose menopausal status is not established (21). 
It stands to reason that the treatment regimen is closely 
associated with menopausal status as well as patient 
age. In this context, menopausal status and age were not 
independently associated with BPE decrease in multivariate 
analysis, as treatment regimen, although the rate of a 
decrease in BPE was significantly higher in younger and 
premenopausal women (Table 3).
Interestingly, MRI-related factors including the difference 
in MRI field strength before and after therapy and BPE 
at baseline MRI were independently associated with the 
decrease in BPE after endocrine therapy. The change from 
1.5T MRI at baseline to 3.0T MRI in the follow-up was 
more likely to show a decrease in BPE compared to both 
MRI studies done at 1.5T or 3.0T. Although the reasons 
for this were not completely understood and investigated 
in the present study, one of them might be the improved 
image quality at 3.0T MRI system. The main improvement 
in using a higher field strength magnet is the increase in 
the signal-to-noise ratio, theoretically, doubling from 1.5T 
to 3.0T, which can be exploited to image at a higher spatial 
resolution and translated into the improved image quality 
by improved morphological details aiding in characterization 
of normal physiological BPE (22, 23). Although higher 
magnetic field strengths have been associated with physical 
effects that are not advantageous to obtain high image 
quality including stronger susceptibility effects, increased 
T1 relaxation times, radiofrequency inhomogeneity, and 
accentuation of certain MR imaging artifacts, previous 
studies reported that image quality was better at 3.0T than 
at 1.5T (24-26). In addition, high contrast-to-noise ratio 
is affected by field strength effects on T1 relaxation times 
of breast tissue and gadolinium. At 3.0T, the T1 relaxation 
time is increased for both fat and glandular tissue in the 
breast by approximately 21% and 17%, respectively, but 
T1 relaxation of gadolinium is increased to a much lesser 
extent (27). This suggests that the relative difference in 
signal intensity between enhancing and nonenhancing 
tissues would be increased at 3.0T, making enhancing tissue 
more conspicuous (23). However, it is currently unclear how 
the T1 relaxation time effect affects BPE in terms of high 
contrast-to-noise ratio at 3.0T and why the change from 
1.5T at baseline to 3.0T in the follow-up was more likely to 
show a decrease in BPE compared to both MR studies done 
at 3.0T in our study. Further investigation of qualitative 
and quantitative comparison between 1.5T and 3.0T MRI is 
needed to prove these speculations.
Regarding BPE status at baseline MRI, women with 
moderate or marked BPE were significantly associated with 
the decrease in BPE after endocrine therapy than those with 
minimal or mild BPE. In a previous study for the effect of 
AI on BPE (7), a similar result was reported; of women with 
moderate or marked BPE, 71% (20 of 28) of those treated 
with anastrozole and 80% (8 of 10) of those treated with 
Fig. 2. Axial contrast-enhanced T1-
weighted subtraction MRI obtained 
150 s after contrast injection in 
a 57-year-old post-menopausal 
woman treated for contralateral 
invasive ductal carcinoma. (a) 
Baseline image before treatment 
with letrozole obtained with 3.0-T 
MRI system shows mild background 
parenchymal enhancement. (b) 
After 22 month from baseline 
study, follow-up 3.0-T MR image 
during treatment with tamoxifen 
shows a mild BPE or no decrease in 
BPE.
a b
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letrozole had a decrease in BPE, whereas 27% (17 of 64) 
and 44% (7 of 16) of women with mild baseline BPE treated 
with anastrozole and letrozole had a decrease, respectively. 
The suggested reason for this observation was that among 
many postmenopausal women who already had a low 
degree of enhancement, substantial further decreases in 
BPE could not be achieved. However, presently there was an 
independent association of baseline BPE with the decrease 
in BPE after therapy, irrespective of treatment regimen and 
menopausal status. Considering that both studies assessed 
BPE using a four-level categorical scale on the basis of the 
side-by-side comparison, the difference in visually assessed 
BPE would seem to be more significant when the baseline 
BPE was moderate or marked than minimal or mild, and 
vice versa. To clarify this result, quantitative measures to 
assess BPE is required. However, no validated and reliable 
quantitative method for measuring BPE was available. 
Although some quantitative methods for measuring overall 
BPE are currently in the early stages of development, they 
were not widely available at this time (15).
This study has some limitations. Owing to its retrospective 
nature, there might have been unavoidable selection bias, 
because only women who underwent breast MRI both 
before and after adjuvant endocrine therapy were included. 
Long-term follow-up data for treatment response or 
recurrence were limited. Further prospective studies will be 
necessary to evaluate the role of BPE as a potential marker 
of response in the adjuvant setting and its associated 
factors. The use of different MRI systems in magnetic field 
strength or vendors can be a limitation. It is difficult to 
make a direct comparison, as the sequence parameters 
and coils for 1.5T and 3.0T are different. For 3.0T MRI, 
two different systems were used randomly, but the same 
protocol was applied. In addition, different types of contrast 
agent were used. It may play a major role in BPE, but was 
not evaluated in the present study.
In conclusion, the different MRI field strength before and 
after therapy and moderate or marked BPE at baseline MRI 
before therapy were associated with the decrease in BPE at 
follow-up MRI after adjuvant endocrine therapy.
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